Venus Remedies has received marketing authorization to sell its anticoagulant, Enoxaparin, in pre-filled syringes across all major strengths in Indonesia, Southeast Asia's largest pharmaceutical market. This approval strengthens the company’s foothold in the region and aligns with its broader expansion strategy. Enoxaparin is used to prevent and treat blood clots, addressing conditions like deep vein thrombosis and pulmonary embolism. With an annual production capacity exceeding 10 million units, Venus Remedies is well-positioned to capture a significant share of the growing anticoagulant market in Southeast Asia.
Source: CNBC-TV18, Express Pharma, The Indian Practitioner.